Home > News > pSivida Given a 'Speculative Buy Class A'
March 28th, 2006
pSivida Given a 'Speculative Buy Class A'
Global bio-nanotech drug delivery company, pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) is featured in a report in the March 24, 2006 issue of Bioshares, a respected Australian independent biotech investment newsletter.
Nanometrics to Participate in the 8th Annual CEO Investor Summit: Investor Event Held Concurrently with SEMICON West 2016 in San Francisco June 22nd, 2016
Artificial synapse rivals biological ones in energy consumption June 21st, 2016
NanoLabNL boosts quality of research facilities as Dutch Toekomstfonds invests firmly June 10th, 2016
Nanometrics Announces Upcoming Investor Events May 10th, 2016
Superheroes are real: Ultrasensitive nonlinear metamaterials for data transfer June 25th, 2016
Russian physicists create a high-precision 'quantum ruler': Physicists have devised a method for creating a special quantum entangled state June 25th, 2016
Nanoscientists develop the 'ultimate discovery tool': Rapid discovery power is similar to what gene chips offer biology June 25th, 2016
Ultrathin, flat lens resolves chirality and color: Multifunctional lens could replace bulky, expensive machines June 25th, 2016